Beyond Air 2025 Q4 Earnings Narrower Losses with 67% Net Income Improvement

Beyond Air (XAIR) reported its fiscal 2025 Q4 earnings on June 20th, 2025. [Beyond Air exceeded expectations for narrowing losses, with earnings per share improving significantly from the previous year. The company's guidance for the upcoming quarter and fiscal year shows strong confidence in growth, aiming to achieve substantial revenue increases. With strategic expansions and innovative product developments, Beyond Air continues to position itself for future success, although challenges remain in achieving profitability.]

Revenue

Earnings/Net Income
Beyond Air narrowed losses to $0.10 per share in 2025 Q4 from a loss of $0.30 per share in 2024 Q4 (67.4% improvement). Meanwhile, the company successfully narrowed its net loss to $-8.06 million in 2025 Q4, reducing losses by 44.6% compared to the $-14.56 million net loss reported in 2024 Q4. The Company has sustained losses for 4 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS improvement signals a positive trend despite ongoing challenges.

Price Action

Post-Earnings Price Action Review
The strategy of buying XAIR when revenues miss and holding for 30 days yielded poor performance. The strategy's CAGR was -48.31%, with an excess return of -124.30% and a Sharpe ratio of -0.68. This indicates significant underperformance and risk, as the volatility was high at 70.94% and the maximum drawdown was -95.40%. This performance suggests that the market has consistently penalized earnings misses, leading to high volatility and substantial losses for investors following this strategy. The data emphasizes the risk associated with trading based on earnings misses and highlights the need for a diversified approach to mitigate potential losses.

CEO Commentary
“Our commercial momentum is building, and that progress is now being reflected in our topline results,” said Steve Lisi, Chairman and Chief Executive Officer. “With LungFit PH now installed and in regular use at more than 45 hospitals nationwide, awareness is accelerating. Regulatory approvals and new international partnerships have driven strong order activity, and we expect sustained double-digit sequential revenue growth moving forward. The submission of the PMA supplement for our second-generation LungFit PH device could be transformative for our business. Coupled with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond Air and our shareholders.”

Guidance
Beyond Air expects to report revenue of at least $1.7 million for the quarter ending June 30, 2025, which represents significant sequential growth. For the fiscal year 2026, the company provides revenue guidance in the range of $12 million to $16 million, indicating strong confidence in continued market adoption and growth potential.

Additional News
Beyond Air announced significant strategic advancements, including the submission of a PMA supplement for the second-generation LungFit PH device, which could enhance its market potential. The company has also expanded its global distribution network, with agreements recently signed for countries such as France, Turkey, Romania, and Morocco, bringing the LungFit PH system to 18 countries. Additionally, Beyond Air appointed Robert Goodman to the Board, bringing extensive experience to support its growth initiatives. These developments highlight Beyond Air's focus on strengthening its market position and advancing its innovative medical technologies.